SEOM Clinical Guideline of management of soft-tissue sarcoma (2020)
Clin. transl. oncol. (Print)
; 23(5): 922-930, mayo 2021. tab, ilus
Article
in En
| IBECS
| ID: ibc-221232
Responsible library:
ES1.1
Localization: ES15.1 - BNCS
ABSTRACT
Soft-tissue sarcomas constitute an uncommon and heterogeneous group of tumors of mesenchymal origin. Diagnosis, treatment, and management should be performed by an expert multidisciplinary team. MRI/CT of the primary tumor and biopsy is mandatory before any treatment. Wide surgical resection with tumor-free tissue margin is the mainstay for localized disease. Radiotherapy is indicated in large, deep, high-grade tumors, or after marginal resection not suitable for re-excision. Perioperative chemotherapy should be discussed for high-risk sarcomas of the extremities and trunk-wall. In the case of oligometastatic disease, patients should be considered for local therapies. First-line treatment with anthracyclines (or in combination with ifosfamide) is the treatment of choice. Other drugs have shown activity in second-line therapy and in specific histological subtypes but options are limited and thus, a clinical trial should always be discussed (AU)
Key words
Full text:
1
Collection:
06-national
/
ES
Database:
IBECS
Main subject:
Sarcoma
/
Soft Tissue Neoplasms
Limits:
Humans
Country/Region as subject:
Europa
Language:
En
Journal:
Clin. transl. oncol. (Print)
Year:
2021
Document type:
Article